<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Idiopathic anaphylaxis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Idiopathic anaphylaxis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Idiopathic anaphylaxis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leslie C Grammer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John M Kelso, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H237063560"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anaphylaxis is often associated with an identifiable trigger, such as a food, medication, or insect sting. Idiopathic anaphylaxis (IA) is diagnosed when no specific trigger can be identified after an appropriate evaluation and when conditions, such as systemic mastocytosis, have been ruled out. (See  <a class="medical medical_review" href="/z/d/html/391.html" rel="external">"Anaphylaxis: Confirming the diagnosis and determining the cause(s)"</a>.)</p><p>This topic will review the pathogenesis, diagnosis, treatment, and prognosis of IA. Other aspects of anaphylaxis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a> and  <a class="medical medical_review" href="/z/d/html/395.html" rel="external">"Differential diagnosis of anaphylaxis in adults and children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Anaphylaxis is defined as a serious allergic reaction that is rapid in onset and may cause death [<a href="#rid1">1</a>]. Symptoms of anaphylaxis involve multiple body organ systems  (<a class="graphic graphic_table graphicRef66333" href="/z/d/graphic/66333.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/106778.html" rel="external">"Anaphylaxis: Acute diagnosis", section on 'Definition'</a>.)</p><p>The diagnosis of IA is made when a patient has signs and symptoms consistent with anaphylaxis, but no specific trigger can be identified, and other diseases have been ruled out [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>IA is more common in adults, although it also occurs in children [<a href="#rid3">3-5</a>]. In several series, up to 70 percent of patients with IA were female, and approximately 50 percent of patients were atopic (defined in the study as having a history of rhinitis or asthma and positive aeroallergen skin test results) [<a href="#rid3">3,6,7</a>]. Patients with IA may also have episodes of anaphylaxis caused by known triggers, such as food, medications, and exercise, but these do not account for all of the anaphylaxis episodes [<a href="#rid3">3</a>]. The prevalence of IA in the United States was estimated at approximately 1 in 10,000 in the mid-1990s [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>IA is associated with widespread mast cell activation, as is anaphylaxis from a known trigger. Mast cells do not appear to be hyperresponsive, although data are limited. Patients with IA also have increased activation of lymphocytes, although the significance of this is not clear [<a href="#rid9">9</a>]. A more detailed discussion of the pathogenesis of anaphylaxis is found separately. (See  <a class="medical medical_review" href="/z/d/html/106778.html" rel="external">"Anaphylaxis: Acute diagnosis", section on 'Causes and mechanisms'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Mast cell activation</span><span class="headingEndMark"> — </span>Patients with IA may have transient elevations in levels of mast cell mediators, including plasma and urinary histamine [<a href="#rid5">5</a>] and serum or plasma total tryptase [<a href="#rid5">5,10</a>], immediately following an episode of anaphylaxis. Between episodes, mediator levels should return to within the normal range. Other disorders with similar elevations in mast cell mediators are discussed below. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>There are no data to support the hypothesis that mast cells in patients with IA are hyperresponsive. In a study of 56 patients with IA, mast cell precursors were collected from peripheral blood, cultured in vitro, and tested for immunoglobulin E (IgE) mediated release of beta-hexosaminidase [<a href="#rid11">11</a>]. Mast cells from patients with IA and healthy controls responded similarly, indicating that the patients' mast cells were not hyperresponsive through the classic IgE-mediated mechanism. However, mast cells have multiple other mechanisms for activation, and other mechanisms have not been specifically studied. The investigators did note that peripheral blood from patients with IA yielded higher mast cell numbers in culture compared with healthy controls for unknown reasons.</p><p class="headingAnchor" id="H6"><span class="h2">Lymphocyte and basophil activation</span><span class="headingEndMark"> — </span>Patients with IA have an increased percentage of activated T cells in their peripheral blood during acute episodes compared with during remission. In addition, they have more activated B cells, both during acute episodes and in remission, than in the general population or in patients with chronic idiopathic urticaria [<a href="#rid9">9</a>]. In microarray analyses, cells from patients with IA differentially express genes that strongly correlate with the level of CD203c, a marker of basophil activation [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H520293440"><span class="h2">Increased gastrointestinal permeability</span><span class="headingEndMark"> — </span>Episodes of IA are often accompanied by gastrointestinal manifestations. Surrogate markers of gastrointestinal permeability, soluble CD14 (sCD14) and intestinal fatty acid binding protein (I-FABP), were reported to be elevated in patients with IA as compared with health controls [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The signs and symptoms of IA are the same as in anaphylaxis resulting from known triggers  (<a class="graphic graphic_table graphicRef66333" href="/z/d/graphic/66333.html" rel="external">table 1</a>). The severity spectrum is also similar. Fatal and near-fatal cases of IA have been reported [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/106778.html" rel="external">"Anaphylaxis: Acute diagnosis", section on 'Definition'</a>.)</p><p class="headingAnchor" id="H2302792550"><span class="h1">EVALUATION AND REFERRAL</span><span class="headingEndMark"> — </span>All patients suspected of having IA should be referred to an allergy specialist because all possible triggers of anaphylaxis and disorders that mimic anaphylaxis should be considered and ruled out before making the diagnosis. IA is established only after performing a comprehensive history, physical examination, review of medical records, and appropriate laboratory tests. Depending on the allergen that is under consideration, testing may involve skin testing, measurement of allergen-specific serum IgE, component-resolved diagnostics, or challenge procedures. (See  <a class="medical medical_review" href="/z/d/html/395.html" rel="external">"Differential diagnosis of anaphylaxis in adults and children"</a>.)</p><p>Patients with possible IA should be supplied with at least two <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors and instructed on how and when to use them if symptoms recur, even before they are evaluated by an allergy specialist. (See  <a class="medical medical_review" href="/z/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment", section on 'Dosing'</a> and  <a class="medical medical_review" href="/z/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment", section on 'Available devices'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Evaluate for possible triggers</span><span class="headingEndMark"> — </span>On occasion, patients who were thought to have IA are found to have unusual triggers of anaphylaxis that were initially overlooked. We review all ingestions (foods, medications, beverages), activities, and changes to baseline health in the hours before each episode that the patient can recall.</p><p class="headingAnchor" id="H3950631946"><span class="h3">Symptoms in association with eating</span><span class="headingEndMark"> — </span>Food-associated triggers should be considered in patients whose reactions occur in close association with eating. Considerations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Undeclared or mislabeled food allergens, or "hidden" food allergens, such as peanut in egg rolls, tree nuts in salad dressing, or soy in canned tuna [<a href="#rid14">14,15</a>]. Patients with food allergy occasionally react to non-food items as well. (See  <a class="medical medical_review" href="/z/d/html/2406.html" rel="external">"Management of food allergy: Avoidance", section on 'Food allergens in nonfood items'</a> and  <a class="medical medical_review" href="/z/d/html/2400.html" rel="external">"Seafood allergies: Fish and shellfish", section on 'Allergy to additives in canned fish'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spices, especially members of the Apiaceae (Umbelliferae) family, which include caraway, coriander, and fennel [<a href="#rid16">16</a>]. Other spices that have been implicated in systemic reactions include garlic, onion, mustard, saffron, parsley, and cumin [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/2403.html" rel="external">"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)", section on 'Celery-mugwort-birch-spice syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergens that can cause reactions in some patients with other food allergies, such as pectin or pink peppercorns in some patients with cashew or pistachio allergies, or lupine flour in some patients with peanut allergies (more common in European populations) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Food causing anaphylaxis in the setting of exercise or when taken in temporal proximity to nonsteroidal antiinflammatory drugs (NSAIDs) or alcohol but not with ingestion of the food alone. The best-described example of anaphylaxis that only occurs when other cofactors are present is wheat-dependent exercise-induced anaphylaxis, which is usually caused by sensitization to the allergen omega-5 gliadin [<a href="#rid17">17,18</a>]. Some experts have suggested that sensitization to omega-5 gliadin be assessed in all cases of apparent IA [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/384.html" rel="external">"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mammalian meat, which can cause delayed (eg, up to several hours after ingestion) anaphylaxis in patients sensitized to the carbohydrate allergen, alpha-gal [<a href="#rid19">19-21</a>]. (See  <a class="medical medical_review" href="/z/d/html/2393.html" rel="external">"Allergy to meats"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Foods contaminated with aeroallergens (eg, "bee pollen"), which often contains ragweed pollen [<a href="#rid22">22,23</a>], flour contaminated with mite allergens (variably called "pancake" syndrome or oral mite anaphylaxis) [<a href="#rid24">24,25</a>], or grain products contaminated with insects [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Food additives, such as carmine powder [<a href="#rid27">27</a>] and <a class="drug drug_general" data-topicid="9834" href="/z/d/drug information/9834.html" rel="external">psyllium</a> [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/2405.html" rel="external">"Allergic and asthmatic reactions to food additives", section on 'Anaphylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergic reactions to <em>Anasakis simplex</em>, a fish nematode, can mimic fish allergy, but symptoms are delayed 2 to 24 hours after the ingestion of fish and testing for specific IgE to fish is negative. This is almost exclusively reported in Spain. (See  <a class="medical medical_review" href="/z/d/html/2400.html" rel="external">"Seafood allergies: Fish and shellfish", section on 'Anisakis'</a>.)</p><p></p><p class="headingAnchor" id="H3134578552"><span class="h3">Medications</span><span class="headingEndMark"> — </span>Medication triggers that should be considered before labeling a patient with IA include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of over-the-counter medications containing NSAIDs that the consumer did not recognize (eg, Alka-Seltzer contains <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of angiotensin-converting enzyme (ACE) inhibitors or combination angiotensin receptor blocker and a neprilysin inhibitor (ARNI) that can cause angioedema [<a href="#rid29">29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/16380.html" rel="external">"ACE inhibitor-induced angioedema", section on 'Future use of related drugs'</a>.)</p><p></p><p class="headingAnchor" id="H3955877163"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other potential triggers include:</p><p class="bulletIndent1"><span class="glyph">●</span>Exercise (alone and/or in combination with prior ingestion of food or medication) [<a href="#rid31">31,32</a>] (see  <a class="medical medical_review" href="/z/d/html/384.html" rel="external">"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Latex exposure [<a href="#rid5">5</a>] (see  <a class="medical medical_review" href="/z/d/html/5543.html" rel="external">"Latex allergy: Epidemiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Undetected insect bites and stings from Hymenoptera, pigeon ticks, or <em>Triatoma</em> [<a href="#rid33">33-35</a>] (see  <a class="medical medical_review" href="/z/d/html/4087.html" rel="external">"Reactions to bites from kissing bugs (primarily genus <i>Triatoma</i>)", section on 'Allergic reactions'</a>)</p><p></p><p class="headingAnchor" id="H2488429238"><span class="h2">Serum tryptase</span><span class="headingEndMark"> — </span>An anaphylaxis episode can be confirmed, in some cases, by acute measurement of serum tryptase or other mast cell mediators in the hours after an episode of symptoms  (<a class="graphic graphic_table graphicRef69698" href="/z/d/graphic/69698.html" rel="external">table 2</a>). The minimal elevation in serum total tryptase level that is considered to be indicative of clinically significant mast cell activation is ≥(2 + 1.2 x baseline tryptase levels) [<a href="#rid36">36</a>]. However, a normal serum tryptase does not exclude the diagnosis of anaphylaxis. (See  <a class="medical medical_review" href="/z/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Elevations in anaphylaxis'</a>.)</p><p>A total tryptase level that is persistently elevated at baseline, rather than only following symptoms, strongly suggests either hereditary alpha tryptasemia or systemic mastocytosis, and further evaluation should be pursued. (See  <a class="medical medical_review" href="/z/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Hereditary alpha tryptasemia'</a> and  <a class="medical medical_review" href="/z/d/html/103174.html" rel="external">"Systemic mastocytosis: Determining the subtype of disease"</a>.)</p><p>There are also disorders that can cause persistently elevated tryptase levels in the absence of allergic or anaphylactic symptoms, such as chronic kidney disease and certain myelodysplastic syndromes. These disorders are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/389.html" rel="external">"Laboratory tests to support the clinical diagnosis of anaphylaxis", section on 'Other conditions'</a>.)</p><p>Further testing should focus on ruling out specific triggers of anaphylaxis or conditions with similar symptoms. Testing should be limited to the evaluation of specific triggers or disorders that are suspected based on the patient's history and examination and measurement of a baseline serum total tryptase level [<a href="#rid37">37,38</a>]. (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a> and  <a class="medical medical_review" href="/z/d/html/395.html" rel="external">"Differential diagnosis of anaphylaxis in adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/8105.html" rel="external">"An overview of angioedema: Clinical features, diagnosis, and management"</a> and  <a class="medical medical_review" href="/z/d/html/2745.html" rel="external">"Overview of shellfish, pufferfish, and other marine toxin poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/2782.html" rel="external">"Approach to flushing in adults"</a>.)</p><p class="headingAnchor" id="H255103970"><span class="h2">Exclusion of a monoclonal mast cell population</span><span class="headingEndMark"> — </span>For patients with difficult-to-control disease or symptoms that change over time or are especially severe, we test for monoclonal mast cell disorders [<a href="#rid39">39</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 30 adults with unexplained anaphylaxis, 47 percent had a clonal mast cell disorder [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subsequent study of 56 patients initially diagnosed with IA, 14 percent were found to have a clonal mast cell disorder [<a href="#rid11">11</a>].</p><p></p><p>To exclude a clonal mast cell disorder, serum tryptase should be measured at baseline and after an episode of symptoms, if not already performed. The issue of how aggressively to search for a clonal mast cell disorder with additional testing in patients with IA is influenced by the patient's degree of disability, and practice differs among experts. The diagnosis of monoclonal mast cell disorders, as well as a discussion of the use of peripheral blood allele-specific quantitative polymerase chain reaction (ASqPCR) for <em>KIT </em>D816V mutations compared with bone marrow biopsy is found separately. (See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'KIT mutational analysis'</a>.)</p><p class="headingAnchor" id="H3654696564"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>IA is a diagnosis of exclusion, by definition. Patients must meet clinical criteria for the diagnosis of anaphylaxis  (<a class="graphic graphic_table graphicRef72225" href="/z/d/graphic/72225.html" rel="external">table 3</a>) and have no identifiable cause. These are the minimum requirements for diagnosis.</p><p class="headingAnchor" id="H948895569"><span class="h2">Classification</span><span class="headingEndMark"> — </span>IA is classified into subgroups based on frequency of episodes and clinical manifestations [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3018876627"><span class="h3">Frequent versus infrequent</span><span class="headingEndMark"> — </span>Frequent IA has been defined as at least two episodes in the preceding two months or at least six episodes in the preceding year [<a href="#rid2">2</a>]. Patients with IA who do not meet one of these criteria are categorized as having infrequent IA.</p><p class="headingAnchor" id="H4162022461"><span class="h3">Generalized versus angioedema</span><span class="headingEndMark"> — </span>IA-generalized is characterized by prominent urticaria with or without angioedema plus other severe systemic symptoms (cardiovascular, respiratory symptoms, and/or gastrointestinal).</p><p>IA-angioedema is the term given to occasional patients whose episodes are characterized by marked upper airway obstruction due to severe angioedema of the tongue, pharynx, and/or larynx. In the author's experience, this type of IA may involve upper airway angioedema plus gastrointestinal pain and hypotension (possibly due to bowel angioedema and third-spacing of fluid).</p><p>If the patient's angioedema cannot be readily visualized, particularly if the throat is involved, it is important that it be objectively confirmed at some point as several other disorders can cause a subjective sensation of throat tightness or swelling. Common etiologies of subjective throat tightness include vocal cord dysfunction and laryngopharyngeal reflux. An endoscopic exam (by an otolaryngologist or other appropriately trained clinician) during an episode of symptoms is critical to distinguishing these disorders from actual angioedema and should be pursued whenever feasible.</p><p class="headingAnchor" id="H13912230"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of IA includes disorders of angioedema, nonanaphylactic disorders, mast cell disorders, and somatoform symptom disorder.</p><p class="headingAnchor" id="H1012421595"><span class="h2">Testing for angioedema disorders</span><span class="headingEndMark"> — </span>In patients whose symptoms are predominantly angioedema without urticaria, disorders causing bradykinin-induced angioedema, such as hereditary angioedema (due to C1 inhibitor deficiency or other defects) and angiotensin-converting enzyme (ACE) inhibitor-induced angioedema, should be considered in the differential diagnosis. A serum level of C4 is a reasonable screen for C1 inhibitor deficiency (inherited or acquired), although there are several forms of episodic angioedema in which complement studies are normal. (See  <a class="medical medical_review" href="/z/d/html/8098.html" rel="external">"Hereditary angioedema (due to C1 inhibitor deficiency): Pathogenesis and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/16529.html" rel="external">"Hereditary angioedema with normal C1 inhibitor"</a>.)</p><p class="headingAnchor" id="H2114702954"><span class="h2">Nonanaphylactic disorders</span><span class="headingEndMark"> — </span>Other disorders should be considered in the differential diagnosis include disorders that cause flushing, severe acute asthma exacerbations, and somatoform and Munchausen disorders. The differential diagnosis of anaphylaxis is discussed extensively in another topic. (See  <a class="medical medical_review" href="/z/d/html/395.html" rel="external">"Differential diagnosis of anaphylaxis in adults and children"</a>.)</p><p class="headingAnchor" id="H72857811"><span class="h2">Mast cell activation disorders</span><span class="headingEndMark"> — </span>Idiopathic mast cell activation syndrome (IMCAS) is similar to IA, but signs and symptoms do not meet criteria for anaphylaxis, usually because patients do not become frankly hypotensive. To make the diagnosis of IMCAS, there must be transient elevations in mast cell mediators, which return to normal in between episodes. The definition of IMCAS and IA are evolving, and some experts suggest that IA is better classified as a subset of IMCAS [<a href="#rid41">41</a>]. Another subset of patients has a monoclonal population of mast cells and can be classified as monoclonal mast cell activation syndrome (MMAS)  (<a class="graphic graphic_table graphicRef74223" href="/z/d/graphic/74223.html" rel="external">table 4</a>). Bone marrow biopsy is sometimes required to conclusively exclude a mast cell disorder [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/15715.html" rel="external">"Mast cell disorders: An overview"</a>.)</p><p class="headingAnchor" id="H1267424406"><span class="h2">Systemic mastocytosis</span><span class="headingEndMark"> — </span>In contrast to IA and mast cell activation disorders, patients with systemic mastocytosis have elevations of serum total tryptase levels that are persistent and are detectable even after resolution of an acute episode [<a href="#rid37">37-39</a>]. Systemic mastocytosis is characterized by a pathologic increase in mast cell numbers in the tissues. (See  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2910409724"><span class="h2">Somatoform symptom disorder</span><span class="headingEndMark"> — </span>Some patients describe subjective symptoms that are consistent with IA but have not had objective signs or symptoms documented, do not have organic disease that can be verified, and do not respond to treatment for IA. For example, patients may report a sensation of throat tightness (ie, globus sensation) and be concerned that their throat may close or that they cannot breathe. It is essential that these patients be evaluated by an otolaryngologist or other provider in the urgent care setting while the symptom is present if episodes become recurrent. Such patients can be very challenging to manage, utilize the emergency department repeatedly, and may meet criteria for somatoform symptom disorder or panic disorder. (See  <a class="medical medical_review" href="/z/d/html/112997.html" rel="external">"Somatic symptom disorder: Assessment and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">TREATMENT OF ACUTE EPISODES</span><span class="headingEndMark"> — </span>Once the diagnosis of IA is entertained, the patient needs to be equipped to self-administer initial treatment for any future episodes.</p><p class="headingAnchor" id="H2284906284"><span class="h2">Initial management</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> is the drug of choice for acute treatment of anaphylaxis, and patients should be counseled that it is the only treatment that prevents or reverses laryngeal edema, severe bronchospasm, and cardiovascular collapse. Failure to administer epinephrine early in the course of treatment has been repeatedly implicated in anaphylaxis fatalities [<a href="#rid43">43-46</a>]. The acute treatment of anaphylaxis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment", section on 'Immediate management'</a>.)</p><p><a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> should be administered as soon as possible when an episode of significant symptoms begins, and the patient should proceed to the nearest emergency department in the safest manner possible (ie, by ambulance if necessary). Patients may also be instructed to take additional medications for specific residual symptoms, although these usually respond to epinephrine as well:</p><p class="bulletIndent1"><span class="glyph">●</span>An H1 antihistamine (either first or second generation, such as <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a>, 10 mg) for pruritus or urticaria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">Albuterol</a> by metered-dose inhaler, 2 puffs inhaled, for bronchospasm</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> 40 or 60 mg (adult dose), for those patients who already have the diagnosis of IA but are not taking prednisone at the time, or are taking a lower dose</p><p></p><p>Patients with IA should have access to at least two <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> autoinjectors and be educated about how and when to self-administer the drug. The different autoinjectors and prefilled syringes available and weight-based dosing are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/388.html" rel="external">"Prescribing epinephrine for anaphylaxis self-treatment"</a>.)</p><p class="headingAnchor" id="H1340341976"><span class="h2">Anaphylaxis action plan</span><span class="headingEndMark"> — </span>Patients and caregivers should be given individualized instructions about how to proceed if symptoms recur. One approach is to provide the patient with a written anaphylaxis action plan. An action plan that can be personalized is available online through the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aaaai.org%2F&amp;token=RxBqIaK4IjVvTPMpPUJnutMMeVmA8xmPyYsKJbu1ibM%3D&amp;TOPIC_ID=387" target="_blank">American Academy of Allergy, Asthma, and Immunology</a> [<a href="#rid47">47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>English – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.aaaai.org%2FAaaai%2Fmedia%2FMediaLibrary%2FPDF+Documents%2FLibraries%2FAnaphylaxis-Emergency-Action-Plan.pdf&amp;token=%2FC5Q%2FiCB%2F2LLCwV7T8HK2lwm6sR%2FkEZoNaIqN%2F73HXSOVycSIPyputPn68SH00rxz4XgltVFJ9rSmMATkiTNtTCeVQHr44rjlSZkcJVXEDbh%2Bx3d7qqBZUqDAak3uoXk%2FI0U9CKYd1MPL7MRKdB8kw%3D%3D&amp;TOPIC_ID=387" target="_blank">Anaphylaxis Emergency Action Plan</a></p><p class="bulletIndent1"><span class="glyph">●</span>Spanish – <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.aaaai.org%2FAaaai%2Fmedia%2FMediaLibrary%2FPDF+Documents%2FSpanish%2FAnaphylaxis-Emergency-Action-Plan-Spanish.pdf&amp;token=Ls%2BBUTXwAuTJRkpRQ4LA1JgGv03onx4w09YFWrjDcTMb8nQK70M4sv3yKBB6Ojk%2FBSHuni4YwWs1wy9vgRTN0JU2OPH9WbcbiuH8WjlQ7CNVIxv%2FGWSD5R2OrOOaPAI%2FdBm3AtkXm1l5Bk3m72nDvg%3D%3D&amp;TOPIC_ID=387" target="_blank">Anaphylaxis Emergency Action Plan</a></p><p></p><p class="headingAnchor" id="H177013110"><span class="h2">Ongoing review of clinical details</span><span class="headingEndMark"> — </span>After each episode of anaphylaxis, it is important to review the details of the episode and events leading up to it. A new clue about a possible etiology may be uncovered, and the clinician can assess whether <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> was administered appropriately and, if not, explore the reasons for any aspects of care that were not optimal. Teaching points for patients at risk for anaphylaxis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis", section on 'Ongoing education for patients'</a>.)</p><p class="headingAnchor" id="H1063678217"><span class="h1">LONG-TERM MANAGEMENT</span><span class="headingEndMark"> — </span>Long-term pharmacologic management depends on the frequency of episodes [<a href="#rid5">5,48</a>]. Recommendations for the management of patients with IA are based on data from observational studies, case reports/series, and clinical experience.</p><p class="headingAnchor" id="H360167542"><span class="h2">Algorithmic approach</span><span class="headingEndMark"> — </span>Our approach to the long-term management of idiopathic anaphylaxis is depicted in an algorithm  (<a class="graphic graphic_algorithm graphicRef121303" href="/z/d/graphic/121303.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3398661"><span class="h2">Patients with infrequent recurrences</span><span class="headingEndMark"> — </span>Patients with infrequent IA (ie, fewer than two episodes in the preceding two months or six episodes in the preceding year) do not usually require preventative therapy. However, it is important to follow up with the patient after each episode and monitor the frequency of attacks. (See <a class="local">'Ongoing review of clinical details'</a> above.)</p><p class="headingAnchor" id="H137233595"><span class="h2">Patients with frequent recurrences</span><span class="headingEndMark"> — </span>Prophylactic therapy is indicated for patients with frequent IA (ie, at least two episodes in the preceding two months or at least six episodes in the preceding year). It can be started at the time of an acute episode or as soon as the diagnosis has been reached.</p><p>With each significant episode of symptoms, it is important to continue to try to find a common exposure or other explanation for the symptoms. If a possible culprit occurs to the patient or clinician, targeted testing can be performed.</p><p class="headingAnchor" id="H1487197558"><span class="h3">Prednisone plus H1 antihistamines</span><span class="headingEndMark"> — </span>The most common approach is a combination of an oral glucocorticoid and an H1 antihistamine, usually for a minimum of two months.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisone</strong><strong> </strong>– We typically initiate <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at the doses suggested below for one week or until the patient's symptoms have resolved [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adults, 40 to 60 mg orally per day (depending on the patient's size and the severity of symptoms)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children, 1 mg/kg orally (up to a maximum of 60 mg) per day</p><p></p><p class="bulletIndent1">Once symptoms have stopped, the same dose of 40 to 60 mg is then given on alternate days for one to two more weeks. In the author's experience, the dose can often be tapered quickly at first (eg, from 60 mg every other day to 40 mg every other day) and then more slowly once the dose has been reduced to 20 or 15 mg every other day. The dose is then further reduced by 5 mg (still on alternate days) every one to two weeks, assuming there are no breakthrough symptoms [<a href="#rid2">2</a>]. Alternate-day therapy is sufficient in most cases to avoid patients becoming Cushingoid.</p><p></p><p class="bulletIndent1">Breakthrough symptoms during the steroid taper are generally milder than the initial episode and may consist of some urticaria with angioedema or other limited symptoms. In response to these, the glucocorticoid dose is increased to the previous dose that appeared to control symptoms, and that dose is continued until the symptoms resolve. The tapering process is then resumed.</p><p></p><p class="bulletIndent1">If this subsequent taper is not tolerated, adjunctive medications (ie, <a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">ketotifen</a>, <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a>, or leukotriene-modifying drugs) can be added, or the patient can be treated with <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> if symptoms are significant and omalizumab is available. (See <a class="local">'Patients with persistent episodes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>H1 antihistamines </strong>– H1 antihistamines are usually administered concomitantly with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. Although only first-generation antihistamines have been studied for the treatment of IA, second-generation antihistamines, such as <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> given at twice standard dosing (ie, 10 mg orally twice daily), are preferred as first-line treatment due to their more favorable benefit-to-risk ratio. In the author's experience, even higher doses of antihistamines, like those used in chronic urticaria, do not provide additional benefit. The H1 antihistamine is often continued after completion of the course of prednisone, especially in patients who are older, have a history of more severe episodes, and have comorbidities. (See  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis", section on 'Adverse effects and safety'</a>.)</p><p></p><p class="headingAnchor" id="H2692099736"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of the combination of glucocorticoids and H1 antihistamines can be estimated from case reports and observational series [<a href="#rid3">3,4,48</a>]. All available studies included both glucocorticoids and antihistamines.</p><p class="bulletIndent1"><span class="glyph">●</span>In the largest published series, 132 of 335 patients were available at the time of data collection [<a href="#rid3">3</a>]. Eighty-seven were in remission, and the duration of remission ranged from 1 to 14 years. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> for frequent episodes had been administered to 56 patients, and approximately 20 percent had recurrent symptoms as the prednisone was tapered. Among those who eventually weaned off it, the duration of alternate-day therapy was 3 months to 13 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 22 pediatric patients, all were treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a>, and some also received an oral sympathomimetic (oral <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">albuterol</a>) [<a href="#rid4">4</a>]. Nineteen of 22 patients had fewer attacks after the initiation of treatment. After completing this therapy, approximately 50 percent of patients went into remission (ie, no episodes and no prednisone treatment in the past year). Some of these patients remained on an H1 antihistamine.</p><p></p><p class="headingAnchor" id="H561832870"><span class="h3">Patients with persistent episodes</span><span class="headingEndMark"> — </span>The term "malignant IA" is used to identify those patients with the most severe form of IA that is resistant to standard therapy. One investigator has classified patients as having malignant IA if the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose required to control symptoms is ≥20 mg daily or 60 mg on alternate days [<a href="#rid49">49</a>]. Published data on this subset of patients are scant. Case reports describe the use of several other medications that may allow patients to eventually wean off prednisone. One or more of these adjunctive medications can be added when patients appear to be responding to the combination of prednisone and an H1 antihistamine but are having trouble reducing the dose of prednisone without experiencing recurrent symptoms  (<a class="graphic graphic_algorithm graphicRef121303" href="/z/d/graphic/121303.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3395218316"><span class="h4">Omalizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">Omalizumab</a>, a monoclonal antibody directed against IgE, has been reported to be effective in several case reports [<a href="#rid50">50-55</a>]. Variable doses have been used. The dosing and adverse effects of omalizumab are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/545.html" rel="external">"Anti-IgE therapy"</a>.)</p><p class="headingAnchor" id="H4002829894"><span class="h4">Other medications</span><span class="headingEndMark"> — </span>Other medications that may help patients wean off glucocorticoids include leukotriene antagonists, <a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">ketotifen</a>, and oral <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a>. A case report of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> also exists.</p><p class="bulletIndent1"><span class="glyph">●</span>Leukotriene antagonists, such as <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a>, have been helpful in some patients [<a href="#rid3">3,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">Ketotifen</a> is an H1 antihistamine/mast cell stabilizer that can cause significant sedation. The oral formulation of ketotifen is not approved for use in the United States or many other countries. The usual initial dose is 2 mg orally two or three times per day [<a href="#rid3">3,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> (dose of 200 mg up to four times daily in patients 13 years or older or 100 mg up to four times daily in patients ages 2 to 12 years) can be helpful for patients with prominent gastrointestinal symptoms. It is generally mixed into a glass of water and taken one hour before meals and then before bed. We typically begin with one or two doses daily and increase gradually to three to four times daily [<a href="#rid3">3</a>]. Some patients do not tolerate this medication because of bloating, cramping, and diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> was reported to be helpful in a single case report of a patient with severe IA and weekly episodes, refractory to antihistamines, leukotriene antagonists, systemic glucocorticoids, a three-food restricted diet (to exclude occult food allergy), and an eight-month trial of <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> [<a href="#rid57">57</a>]. Rituximab (dose of 1000 mg intravenously) was administered, and, after a second dose (two weeks after the first), the episodes stopped and did not recur until her B cell counts recovered nine months later. She was then retreated at six-month intervals.</p><p></p><p class="headingAnchor" id="H3402856336"><span class="h2">Medications to be avoided</span><span class="headingEndMark"> — </span>Beta blockers should be avoided, if possible, in patients with IA since they may interfere with the response to <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid5">5</a>]. Other general measures in the long-term management of patients with anaphylaxis are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15817.html" rel="external">"Long-term management of patients with anaphylaxis"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most patients experience their most severe symptoms during the first attack, after which they recognize early symptoms and are better able to initiate treatment promptly [<a href="#rid2">2</a>]. The long-term natural history of IA is favorable, even without preventative therapy. Patients who initially present with infrequent episodes rarely progress to frequent episodes [<a href="#rid3">3,58</a>].</p><p>With long-term follow-up, over 90 percent of patients with frequent IA and 65 percent with infrequent IA are considered to be in remission (ie, no episodes and no requirement for <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> therapy in the past year) after a few years [<a href="#rid5">5</a>]. Recurrence after remission is rare [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2802173333"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105526.html" rel="external">"Society guideline links: Anaphylaxis"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The diagnosis of idiopathic anaphylaxis (IA) is made when a patient has signs and symptoms consistent with anaphylaxis  (<a class="graphic graphic_table graphicRef66333" href="/z/d/graphic/66333.html" rel="external">table 1</a>), but no specific trigger can be identified after a thorough evaluation, and other diseases have been ruled out. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – IA is more common in females than males. It is uncommon in children. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The signs and symptoms of IA are the same as those in anaphylaxis resulting from known triggers, and the diagnostic criteria are identical  (<a class="graphic graphic_table graphicRef72225" href="/z/d/graphic/72225.html" rel="external">table 3</a>). Fatal and near-fatal cases of IA have been reported. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of acute episodes</strong> – Acute treatment of IA is identical to acute treatment of anaphylaxis of any etiology. All patients with IA, including those with infrequent episodes, should be equipped with an <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> autoinjector and an anaphylaxis emergency action plan to manage initial treatment of acute anaphylaxis. (See <a class="local">'Treatment of acute episodes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification based on frequency of episodes</strong> – IA is categorized as frequent (at least two episodes in the past two months or six or more episodes in the past year) or infrequent (one or no episodes in the past two months or less than six episodes in the past year). (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventative therapies</strong> – For patients with frequent IA, we suggest prophylactic treatment with the combination of an oral glucocorticoid, such as <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, and a low-sedating H1 antihistamine, such as <a class="drug drug_general" data-topicid="9236" href="/z/d/drug information/9236.html" rel="external">cetirizine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We start with an initial dose of prednisone (in adults) of 40 to 60 mg daily until symptoms have resolved, then change to alternate-day therapy and gradually begin to lower the dose over approximately six to eight weeks. Our approach is summarized in an algorithm  (<a class="graphic graphic_algorithm graphicRef121303" href="/z/d/graphic/121303.html" rel="external">algorithm 1</a>). (See <a class="local">'Long-term management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options for persistent attacks</strong> – For patients who are unable to discontinue oral glucocorticoids without recurrence of symptoms, several other medications can be tried, including <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a>, <a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">ketotifen</a>, oral <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a>, leukotriene modifiers, and <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>. (See <a class="local">'Patients with persistent episodes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most patients with IA go into remission (ie, no episodes and no <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> therapy in the preceding year) after a few years. Recurrence after remission is rare. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.</a></li><li><a class="nounderline abstract_t">Fenny N, Grammer LC. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2015; 35:349.</a></li><li><a class="nounderline abstract_t">Ditto AM, Harris KE, Krasnick J, et al. Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol 1996; 77:285.</a></li><li><a class="nounderline abstract_t">Ditto AM, Krasnick J, Greenberger PA, et al. Pediatric idiopathic anaphylaxis: experience with 22 patients. J Allergy Clin Immunol 1997; 100:320.</a></li><li><a class="nounderline abstract_t">Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:273.</a></li><li><a class="nounderline abstract_t">Tejedor Alonso MA, Sastre DJ, Sanchez-Hernandez JJ, et al. Idiopathic anaphylaxis: a descriptive study of 81 patients in Spain. Ann Allergy Asthma Immunol 2002; 88:313.</a></li><li><a class="nounderline abstract_t">Webb LM, Lieberman P. Anaphylaxis: a review of 601 cases. Ann Allergy Asthma Immunol 2006; 97:39.</a></li><li><a class="nounderline abstract_t">Patterson R, Hogan MB, Yarnold PR, Harris KE. Idiopathic anaphylaxis. An attempt to estimate the incidence in the United States. Arch Intern Med 1995; 155:869.</a></li><li><a class="nounderline abstract_t">Grammer LC, Shaughnessy MA, Harris KE, Goolsby CL. Lymphocyte subsets and activation markers in patients with acute episodes of idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2000; 85:368.</a></li><li><a class="nounderline abstract_t">Shanmugam G, Schwartz LB, Khan DA. Prolonged elevation of serum tryptase in idiopathic anaphylaxis. J Allergy Clin Immunol 2006; 117:950.</a></li><li><a class="nounderline abstract_t">Carter MC, Desai A, Komarow HD, et al. A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. J Allergy Clin Immunol 2018; 141:180.</a></li><li><a class="nounderline abstract_t">Howell DL, Jacobs C, Metz G, et al. Molecular profiling distinguishes patients with active idiopathic anaphylaxis from normal volunteers and reveals novel aspects of disease biology. J Allergy Clin Immunol 2009; 123:S150 (Abstract).</a></li><li><a class="nounderline abstract_t">Cao VT, Carter MC, Brenchley JM, et al. sCD14 and Intestinal Fatty Acid Binding Protein Are Elevated in the Serum of Patients With Idiopathic Anaphylaxis. J Allergy Clin Immunol Pract 2023; 11:2080.</a></li><li><a class="nounderline abstract_t">Furlong TJ, DeSimone J, Sicherer SH. Peanut and tree nut allergic reactions in restaurants and other food establishments. J Allergy Clin Immunol 2001; 108:867.</a></li><li><a class="nounderline abstract_t">Baker MG, Saf S, Tsuang A, Nowak-Wegrzyn A. Hidden allergens in food allergy. Ann Allergy Asthma Immunol 2018; 121:285.</a></li><li><a class="nounderline abstract_t">Moneret-Vautrin DA, Morisset M, Lemerdy P, et al. Food allergy and IgE sensitization caused by spices: CICBAA data (based on 589 cases of food allergy). Allerg Immunol (Paris) 2002; 34:135.</a></li><li><a class="nounderline abstract_t">Heaps A, Carter S, Selwood C, et al. The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis. Clin Exp Immunol 2014; 177:483.</a></li><li><a class="nounderline abstract_t">Kennard L, Thomas I, Rutkowski K, et al. A Multicenter Evaluation of Diagnosis and Management of Omega-5 Gliadin Allergy (Also Known as Wheat-Dependent Exercise-Induced Anaphylaxis) in 132 Adults. J Allergy Clin Immunol Pract 2018; 6:1892.</a></li><li><a class="nounderline abstract_t">Commins SP, Platts-Mills TA. Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol 2009; 124:652.</a></li><li><a class="nounderline abstract_t">Carter MC, Ruiz-Esteves KN, Workman L, et al. Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis. Allergy 2018; 73:1131.</a></li><li><a class="nounderline abstract_t">Pattanaik D, Lieberman P, Lieberman J, et al. The changing face of anaphylaxis in adults and adolescents. Ann Allergy Asthma Immunol 2018; 121:594.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Flais MJ. Bee pollen-induced anaphylactic reaction in an unknowingly sensitized subject. Ann Allergy Asthma Immunol 2001; 86:239.</a></li><li><a class="nounderline abstract_t">Choi JH, Jang YS, Oh JW, et al. Bee Pollen-Induced Anaphylaxis: A Case Report and Literature Review. Allergy Asthma Immunol Res 2015; 7:513.</a></li><li><a class="nounderline abstract_t">Sánchez-Borges M, Fernandez-Caldas E. Hidden allergens and oral mite anaphylaxis: the pancake syndrome revisited. Curr Opin Allergy Clin Immunol 2015; 15:337.</a></li><li><a class="nounderline abstract_t">Takahashi K, Taniguchi M, Fukutomi Y, et al. Oral mite anaphylaxis caused by mite-contaminated okonomiyaki/ pancake-mix in Japan: 8 case reports and a review of 28 reported cases. Allergol Int 2014; 63:51.</a></li><li><a class="nounderline abstract_t">Galant-Swafford J, Zuraw BL, Herschbach J, et al. What is in your pantry? Entomologic anaphylaxis. Allergy Asthma Proc 2020; 41:290.</a></li><li><a class="nounderline abstract_t">DiCello MC, Myc A, Baker JR Jr, Baldwin JL. Anaphylaxis after ingestion of carmine colored foods: two case reports and a review of the literature. Allergy Asthma Proc 1999; 20:377.</a></li><li><a class="nounderline abstract_t">Khalili B, Bardana EJ Jr, Yunginger JW. Psyllium-associated anaphylaxis and death: a case report and review of the literature. Ann Allergy Asthma Immunol 2003; 91:579.</a></li><li><a class="nounderline abstract_t">Sondhi D, Lippmann M, Murali G. Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital. Chest 2004; 126:400.</a></li><li><a class="nounderline abstract_t">Eworuke E, Welch EC, Haug N, et al. Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors. J Am Coll Cardiol 2023; 81:321.</a></li><li><a class="nounderline abstract_t">Castells MC, Horan RF, Sheffer AL. Exercise-induced Anaphylaxis. Curr Allergy Asthma Rep 2003; 3:15.</a></li><li><a class="nounderline abstract_t">Beaudouin E, Renaudin JM, Morisset M, et al. Food-dependent exercise-induced anaphylaxis--update and current data. Eur Ann Allergy Clin Immunol 2006; 38:45.</a></li><li><a class="nounderline abstract_t">Moffitt JE, Venarske D, Goddard J, et al. Allergic reactions to Triatoma bites. Ann Allergy Asthma Immunol 2003; 91:122.</a></li><li><a class="nounderline abstract_t">Stoevesandt J, Grundmeier N, Trautmann A. Gastroesophageal hymenoptera stings add to causes of idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2012; 108:125.</a></li><li><a class="nounderline abstract_t">Rolla G, Heffler E, Boita M, et al. Pigeon tick bite: A neglected cause of idiopathic nocturnal anaphylaxis. Allergy 2018; 73:958.</a></li><li><a class="nounderline abstract_t">Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157:215.</a></li><li><a class="nounderline abstract_t">Müller UR. Elevated baseline serum tryptase, mastocytosis and anaphylaxis. Clin Exp Allergy 2009; 39:620.</a></li><li><a class="nounderline abstract_t">Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63:226.</a></li><li><a class="nounderline abstract_t">Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007; 110:2331.</a></li><li><a class="nounderline abstract_t">Gülen T, Hägglund H, Sander B, et al. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy 2014; 44:1179.</a></li><li><a class="nounderline abstract_t">Akin C. Mast cell activation syndromes. J Allergy Clin Immunol 2017; 140:349.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Metcalfe DD. Controversies in Allergy: Is a Bone Marrow Biopsy Optional or Essential in the Evaluation of the Patient with a Suspected Mast Cell Disorder? J Allergy Clin Immunol Pract 2019; 7:1134.</a></li><li><a class="nounderline abstract_t">Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.</a></li><li><a class="nounderline abstract_t">Bock SA, Muñoz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.</a></li><li><a class="nounderline abstract_t">Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.</a></li><li><a class="nounderline abstract_t">Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252.</a></li><li><a class="nounderline abstract_t">Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.</a></li><li><a class="nounderline abstract_t">Boxer MB, Greenberger PA, Patterson R. The impact of prednisone in life-threatening idiopathic anaphylaxis: reduction in acute episodes and medical costs. Ann Allergy 1989; 62:201.</a></li><li><a class="nounderline abstract_t">Patterson R, Wong S, Dykewicz MS, Harris KE. Malignant idiopathic anaphylaxis. J Allergy Clin Immunol 1990; 85:86.</a></li><li><a class="nounderline abstract_t">Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009; 102:257.</a></li><li><a class="nounderline abstract_t">Demirtürk M, Gelincik A, Colakoğlu B, et al. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 2012; 39:552.</a></li><li><a class="nounderline abstract_t">Jones JD, Marney SR Jr, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 2008; 101:550.</a></li><li><a class="nounderline abstract_t">Lee J. Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy. Asia Pac Allergy 2014; 4:126.</a></li><li><a class="nounderline abstract_t">Pitt TJ, Cisneros N, Kalicinsky C, Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol 2010; 126:415.</a></li><li><a class="nounderline abstract_t">Özdemir Ö, Bozkurt HB, Elmas B. Omalizumab's role in the treatment of steroid dependent malignant idiopathic anaphylaxis. Turk Pediatri Ars 2017; 52:105.</a></li><li><a class="nounderline abstract_t">Patterson R, Fitzsimons EJ, Choy AC, Harris KE. Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen. Ann Allergy Asthma Immunol 1997; 79:138.</a></li><li><a class="nounderline abstract_t">Borzutzky A, Morales PS, Mezzano V, et al. Induction of remission of idiopathic anaphylaxis with rituximab. J Allergy Clin Immunol 2014; 134:981.</a></li><li><a class="nounderline abstract_t">Khan DA, Yocum MW. Clinical course of idiopathic anaphylaxis. Ann Allergy 1994; 73:370.</a></li></ol></div><div id="topicVersionRevision">Topic 387 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461139" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25841556" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8885805" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Idiopathic anaphylaxis: a series of 335 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314343" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pediatric idiopathic anaphylaxis: experience with 22 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17493503" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11926626" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Idiopathic anaphylaxis: a descriptive study of 81 patients in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16892779" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anaphylaxis: a review of 601 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717796" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Idiopathic anaphylaxis. An attempt to estimate the incidence in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11101177" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lymphocyte subsets and activation markers in patients with acute episodes of idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630958" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prolonged elevation of serum tryptase in idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28629749" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Molecular profiling distinguishes patients with active idiopathic anaphylaxis from normal volunteers and reveals novel aspects of disease biology</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36997122" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : sCD14 and Intestinal Fatty Acid Binding Protein Are Elevated in the Serum of Patients With Idiopathic Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11692117" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Peanut and tree nut allergic reactions in restaurants and other food establishments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30219174" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hidden allergens in food allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12078423" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Food allergy and IgE sensitization caused by spices: CICBAA data (based on 589 cases of food allergy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24654858" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477569" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A Multicenter Evaluation of Diagnosis and Management of Omega-5 Gliadin Allergy (Also Known as Wheat-Dependent Exercise-Induced Anaphylaxis) in 132 Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815111" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29161766" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Identification of alpha-gal sensitivity in patients with a diagnosis of idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30071303" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The changing face of anaphylaxis in adults and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11258697" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bee pollen-induced anaphylactic reaction in an unknowingly sensitized subject.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25749764" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bee Pollen-Induced Anaphylaxis: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26110684" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hidden allergens and oral mite anaphylaxis: the pancake syndrome revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24569151" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Oral mite anaphylaxis caused by mite-contaminated okonomiyaki/ pancake-mix in Japan: 8 case reports and a review of 28 reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32605699" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : What is in your pantry? Entomologic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10624494" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Anaphylaxis after ingestion of carmine colored foods: two case reports and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700444" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Psyllium-associated anaphylaxis and death: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302724" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Airway compromise due to angiotensin-converting enzyme inhibitor-induced angioedema: clinical experience at a large community teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36697132" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Comparative Risk of Angioedema With Sacubitril-Valsartan vs Renin-Angiotensin-Aldosterone Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12542988" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Exercise-induced Anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16711535" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Food-dependent exercise-induced anaphylaxis--update and current data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952105" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Allergic reactions to Triatoma bites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22289734" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Gastroesophageal hymenoptera stings add to causes of idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29083476" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pigeon tick bite: A neglected cause of idiopathic nocturnal anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22041891" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400907" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Elevated baseline serum tryptase, mastocytosis and anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18186813" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638853" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25039926" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The presence of mast cell clonality in patients with unexplained anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780942" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mast cell activation syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30630762" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Controversies in Allergy: Is a Bone Marrow Biopsy Optional or Essential in the Evaluation of the Patient with a Suspected Mast Cell Disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1294076" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fatal and near-fatal anaphylactic reactions to food in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17306354" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Further fatalities caused by anaphylactic reactions to food, 2001-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349682" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Further fatal allergic reactions to food in the United Kingdom, 1999-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17378256" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Fatal anaphylaxis: postmortem findings and associated comorbid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461138" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Anaphylaxis, killer allergy: long-term management in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2564265" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The impact of prednisone in life-threatening idiopathic anaphylaxis: reduction in acute episodes and medical costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299110" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Malignant idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19354075" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Omalizumab in idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22390871" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Promising option in the prevention of idiopathic anaphylaxis: omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19055211" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Idiopathic anaphylaxis successfully treated with omalizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24809019" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20624653" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Successful treatment of idiopathic anaphylaxis in an adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28747843" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Omalizumab's role in the treatment of steroid dependent malignant idiopathic anaphylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291418" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018095" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Induction of remission of idiopathic anaphylaxis with rituximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944007" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Clinical course of idiopathic anaphylaxis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
